Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Farmers Insurance
Queensland Health
Cantor Fitzgerald
Express Scripts

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,739,152

« Back to Dashboard

Summary for Patent: 5,739,152

Title: Pharmaceutical emulsion
Abstract:A pharmaceutical emulsion for intravenous administration is disclosed which comprises a) a short acting dihydropyridine compound; b) a lipid phase; c) an emulsifier and d) water or a buffer.
Inventor(s): Andersson; Kjell Hjalmar (Fjar.ang.s, SE), Byrod; Eva Kristina (Molndal, SE), Hansson; Anna-Carin (Goteborg, SE), Nordlander; Margareta (Askim, SE), Westerlund; Rolf Christer (Molndal, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/364,953
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Delivery;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,739,152

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9303744Nov 12, 1993
PCT Information
PCT FiledNovember 03, 1994PCT Application Number:PCT/SE94/01032
PCT Publication Date:May 18, 1995PCT Publication Number: WO95/13066

International Patent Family for Patent: 5,739,152

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel111345► Subscribe
HungaryT74474► Subscribe
Hungary9601268► Subscribe
Czech Republic290772► Subscribe
Germany69429871► Subscribe
Denmark0727997► Subscribe
Estonia03223► Subscribe
Egypt20764► Subscribe
European Patent Office0727997► Subscribe
Spain2172572► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Daiichi Sankyo
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus